BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
📌TL;DR
Gilead (GILD) is acquiring Ouro Medicines for $1.675B upfront (+$500M milestones) to add OM336, a BCMAxCD3 T-cell engager that showed "transformative efficacy" in autoimmune hemolytic anemia and ITP after a single treatment cycle. Galapagos is splitting the deal 50/50.
Sanofi (SNY) licensed Kali Therapeutics' trispecific T-cell engager KT501 (CD3/CD19/BCMA) for $180M upfront and up to $1.05B in milestones. The drug just entered Phase 1 for rheumatoid arthritis this month.
The Paradigm Shift: Two major pharma companies committed over $3 billion to T-cell engagers in autoimmune disease on the exact same day. This is no longer a trend; it's a strategic consensus.
⚡ Executive Takeaway
Monday will be remembered as the day T-cell engagers crossed from oncology curiosity into absolute autoimmune conviction. Gilead and Sanofi, on the same day, committed a combined $3 billion+ in upfront and milestone payments to acquire or license early-stage T-cell engager assets targeting B-cell depletion in autoimmune disease. The signal is impossible to ignore.
Gilead's $1.675B acquisition of Ouro Medicines adds gamgertamig (OM336), a BCMAxCD3 bispecific that demonstrated "transformative efficacy" after a single subcutaneous treatment cycle. Hours later, Sanofi announced it had licensed KT501, a trispecific antibody that simultaneously binds CD3, CD19, and BCMA. The thesis behind both massive bets is identical: T-cell engagers can induce a durable immune "reset" by depleting pathogenic B cells through a short, finite treatment course. If the clinical data holds, this represents a structural paradigm shift from chronically managing autoimmune disease to functionally curing it. 👉 Read Full Analysis
🔮 What To Watch
Gilead/Ouro Integration: Registrational studies for OM336 are expected to start in 2027. Interim Phase 1/2 data later in 2026 will be the next major clinical catalyst. The Galapagos collaboration terms are still being finalized; watch for the formal agreement.
Sanofi/Kali KT501 Data: The Phase 1 trial in rheumatoid arthritis just started enrolling this month, with estimated completion in August 2027. Initial safety and pharmacodynamic data will be critical to validate the trispecific mechanism.
Rocket Pharma (Friday, March 28): Kresladi PDUFA for LAD-I gene therapy is just three days away.
ACC.26 (March 28-30): The American College of Cardiology meeting in New Orleans kicks off this weekend.
Orforglipron (April 10): Lilly's oral GLP-1 target action date approaches.
🚀 Top Story
Gilead Bets $1.675B on Autoimmune Reset with Ouro Medicines
What Happened: Gilead Sciences (GILD) announced a definitive agreement to acquire Ouro Medicines, a privately held biotech developing T-cell engager therapies for autoimmune diseases, for $1.675B upfront in cash plus up to $500M in contingent milestones.
The Asset: The deal centers on OM336 (gamgertamig), a clinical-stage BCMAxCD3 bispecific T-cell engager designed to enable rapid, deep B-cell depletion after a limited subcutaneous treatment course. In ongoing Phase 1/2 studies, OM336 demonstrated "transformative efficacy and a differentiated safety profile" after a single treatment cycle in autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).
The Galapagos Angle: Gilead is in advanced discussions with Galapagos (GLPG) for a 50/50 collaboration on the Ouro portfolio. Under the contemplated terms, Galapagos would pay half the upfront consideration and half of any milestone payments, with royalties of 20-23% of net sales. This could inject genuine strategic purpose into a Gilead-Galapagos partnership that had been widely viewed as directionless.
Executive Impact: This is Gilead's second major acquisition in a month (following the $7.8B Arcellx deal). The company is explicitly building a two-modality autoimmune franchise: CAR-T for deep immune reconstitution, and T-cell engagers for shorter-course immune depletion. Registrational studies for OM336 are expected in 2027.
🏢 Corporate & Business Developments
Sanofi Returns to T-Cell Engagers with $1.23B Kali Deal
What Happened: Sanofi (SNY) signed an exclusive worldwide license agreement with Kali Therapeutics for KT501, a trispecific T-cell engager that simultaneously targets CD3, CD19, and BCMA on B-lineage cells. Kali will receive $180M upfront, with up to $1.05B in milestones plus tiered royalties.
The Science: KT501 uses Kali's proprietary CD3 masking platform to decouple potency from toxicity, aiming to maximize B-cell depletion while minimizing cytokine release syndrome (CRS). The drug just entered a Phase 1 trial in adults with moderately to severely active rheumatoid arthritis this month.
Executive Impact: This marks Sanofi's aggressive return to TCE territory after selling off three clinical-stage TCEs to Vir Biotechnology in 2024. The company is betting that trispecific engagement of CD3, CD19, and BCMA simultaneously will produce deeper and more durable B-cell depletion than standard dual-target approaches.
🔬 Clinical & Research Updates
Vaxcyte Completes Pivotal Pneumococcal Vaccine Enrollment
What Happened: Vaxcyte (PCVX) announced the completion of enrollment in both OPUS-1 and OPUS-2, its Phase 3 trials evaluating VAX-31, a 31-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease and pneumonia in adults.
The Context: VAX-31 covers significantly more serotypes than Pfizer's Prevnar 20 or Merck's Vaxneuvance (15-valent). Completing enrollment in both pivotal trials simultaneously is a meaningful de-risking event; topline data timing will be the next major catalyst to watch.
Lexicon and Novo Nordisk Initiate Phase 1 of Oral Obesity Drug
What Happened: Lexicon Pharmaceuticals and Novo Nordisk announced the initiation of a Phase 1 study for LX9851, an oral obesity drug candidate being developed under their collaboration.
Executive Impact: This marks another entrant in the increasingly crowded oral obesity space. While the Novo Nordisk partnership adds undeniable credibility, LX9851 is years behind Lilly's orforglipron and Novo's own oral Wegovy. It is worth tracking, but not yet a material competitive factor.
🔒 BioMed Nexus Pro — Institutional Intelligence Brief
In Today's Pro Brief:
🧠 The Autoimmune Reset Thesis: Why two $1B+ TCE deals on the exact same day signals a structural inflection for the entire autoimmune treatment paradigm.
⚖️ Gilead's Two-Modality Playbook: How CAR-T and TCEs create complementary approaches to immune reconstitution versus immune depletion.
🧮 Sanofi's Immunology Spending Spree: The cumulative dealmaking math and what it tells you about post-Hudson strategic urgency.
Selective 2026 sponsorship placements are available
Reply directly to discuss a partnership or submit an inquiry here